In last trading session, Seelos Therapeutics, Inc. (NASDAQ:SEEL) saw 1,506,051 shares changing hands with its beta currently measuring 2.19. Company’s recent per share price level of $0.81 trading at $0.02 or 2.25% at ring of the bell on the day assigns it a market valuation of $43.13 Million. That closing price of SEEL’s stock is at a discount of -111.11% from its 52-week high price of $1.71 and is indicating a premium of 48.15% from its 52-week low price of $0.42. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 560.9 Million shares which gives us an average trading volume of 1.33 Million if we extend that period to 3-months.
For Seelos Therapeutics, Inc. (SEEL), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2. Splitting up the data highlights that, out of 2 analysts covering the stock, none rated the stock as a Sell while none recommended an Overweight rating for the stock. None suggested the stock as a Hold whereas 2 see the stock as a Buy. None analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.08 in the current quarter.
Seelos Therapeutics, Inc. (NASDAQ:SEEL) trade information
Upright in the green today for gaining 2.25%, in the last five days SEEL remained trading in the green while hitting it’s week-highest on Friday, Nov 13 when the stock touched $0.92 price level, adding 12.25% to its value on the day. Seelos Therapeutics, Inc.’s shares saw a change of -39.75% in year-to-date performance and have moved -12.06% in past 5-day. Seelos Therapeutics, Inc. (NASDAQ:SEEL) showed a performance of -2.42% in past 30-days. Number of shares sold short was 398.13 Million shares which calculate 299.35 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $8 to the stock, which implies a rise of 887.65% to its current value. Analysts have been projecting $4 as a low price target for the stock while placing it at a high target of $12. It follows that stock’s current price would jump +1381.48% in reaching the projected high whereas dropping to the targeted low would mean a loss of 393.83% for stock’s current value.
Seelos Therapeutics, Inc. (SEEL) estimates and forecasts
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 56.9% during past 5 years. In 2020, company’s earnings growth rate is likely to be around -123.8% while estimates for its earnings growth in next 5 years are of 0%
Seelos Therapeutics, Inc. (NASDAQ:SEEL)’s Major holders
Insiders are in possession of 13.38% of company’s total shares while institution are holding 10.27% percent of that, with stock having share float percentage of 11.85%. Investors also watch the number of corporate investors in a company very closely, which is 38 institutions for Seelos Therapeutics, Inc. that are currently holding shares of the company. Uniplan Investment Counsel, Inc. is the top institutional holder at SEEL for having 2.03 Million shares of worth $1.9 Million. And as of September 29, 2020, it was holding 3.81% of the company’s outstanding shares.
The second largest institutional holder is Renaissance Technologies, LLC, which was holding about 591.09 Thousand shares on September 29, 2020. The number of shares represents firm’s hold over 1.11% of outstanding shares, having a total worth of $553.85 Thousand.
On the other hand, Vanguard Extended Market Index Fund and Fidelity Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of June 29, 2020, the former fund manager was holding 285349 shares of worth $288.2 Thousand or 0.53% of the total outstanding shares. The later fund manager was in possession of 88.25 Thousand shares on August 30, 2020, making its stake of worth around $80.33 Thousand in the company or a holder of 0.17% of company’s stock.